China National Pharmaceutical Group
GPTKB entity
Statements (87)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
gptkb:Sinopharm_Group
various companies GSK's consumer healthcare business in China |
| gptkbp:acquisition |
gptkb:Sinopharm
gptkb:China_National_Pharmaceutical_Group_Co.,_Ltd. |
| gptkbp:ceo |
Liu Jian
|
| gptkbp:employees |
over 100,000
|
| gptkbp:employs |
over 100,000 people
|
| gptkbp:focuses_on |
research and development
|
| gptkbp:founded |
gptkb:1998
|
| gptkbp:global_presence |
yes
|
| gptkbp:has_part |
distribution network
|
| gptkbp:headquarters |
gptkb:Beijing,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
China National Pharmaceutical Group
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:investment |
R& D
|
| gptkbp:is_displayed_in |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:market |
gptkb:China
|
| gptkbp:offers |
gptkb:medical_devices
vaccines diagnostic products |
| gptkbp:operates_in |
gptkb:pharmaceuticals
international markets |
| gptkbp:parent_company |
gptkb:Sinopharm
gptkb:China_National_Chemical_Corporation gptkb:China_National_Pharmaceutical_Group_Corporation gptkb:State-owned_Assets_Supervision_and_Administration_Commission |
| gptkbp:partnership |
gptkb:World_Health_Organization
China National Pharmaceutical Group and Daiichi Sankyo China National Pharmaceutical Group and H. Lundbeck A/ S China National Pharmaceutical Group and Amgen China National Pharmaceutical Group and Astellas China National Pharmaceutical Group and Bayer China National Pharmaceutical Group and Biogen China National Pharmaceutical Group and Eli Lilly China National Pharmaceutical Group and Grifols China National Pharmaceutical Group and Illumina China National Pharmaceutical Group and Ipsen China National Pharmaceutical Group and Merck China National Pharmaceutical Group and Novartis China National Pharmaceutical Group and Pfizer China National Pharmaceutical Group and Roche China National Pharmaceutical Group and Sandoz China National Pharmaceutical Group and Sanofi China National Pharmaceutical Group and Servier China National Pharmaceutical Group and Takeda China National Pharmaceutical Group and UCB China National Pharmaceutical Group and Regeneron Pharmaceuticals China National Pharmaceutical Group and Glaxo Smith Kline China National Pharmaceutical Group and CSL Limited China National Pharmaceutical Group and Vertex Pharmaceuticals China National Pharmaceutical Group and Otsuka Pharmaceutical China National Pharmaceutical Group and Astra Zeneca China National Pharmaceutical Group and Chugai Pharmaceutical China National Pharmaceutical Group and Johnson & Johnson China National Pharmaceutical Group and Kyowa Kirin China National Pharmaceutical Group and Sumitomo Dainippon Pharma China National Pharmaceutical Group and Merck KGa A |
| gptkbp:partnerships |
gptkb:WHO
|
| gptkbp:produces |
gptkb:traditional_medicine
generic drugs biopharmaceuticals |
| gptkbp:products |
gptkb:pharmaceuticals
gptkb:medical_devices generic drugs medications vaccines biologics biopharmaceuticals blood products diagnostics chemical drugs medicines |
| gptkbp:research_focus |
vaccines
biologics |
| gptkbp:revenue |
over $30 billion
$40 billion (2020) |
| gptkbp:subsidiaries |
gptkb:China_National_Pharmaceutical_Corporation
gptkb:Sinopharm |
| gptkbp:subsidiary |
gptkb:Sinopharm
gptkb:Sinopharm_Group_Co.,_Ltd. |
| gptkbp:type |
gptkb:state-owned_enterprise
|
| gptkbp:website |
www.sinopharm.com
|
| gptkbp:bfsParent |
gptkb:Ali_Health
gptkb:2008_Beijing_Olympics |
| gptkbp:bfsLayer |
5
|